A phase I/II study of Cetuximab combined with irinotecan and S-1 as first line therapy in metastatic colorectal cancer patients with KRAS wild type
Not Applicable
- Conditions
- advanced colorectal cancer
- Registration Number
- JPRN-UMIN000004403
- Lead Sponsor
- Kanagawa Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Patients are excluded from this trial for any of the following exclusion criteria: symptomatic infectious disease, bleeding tendency, severe heart disease, pre-existing symptomatic peripheral neuropathy, active double cancer, symptomatic ascites, pregnancy, breast feeding, obstructive bowel disease, severe diabetes mellitus requiring insulin or past history of drug allergy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Phase I study To evaluate feasibility Phase II study Response rate
- Secondary Outcome Measures
Name Time Method